Cauza E, Hanusch-Enserer U, Frischmuth K, Fabian B, Dunky A, Kostner K
Department of Internal Medicine V, Wilhelminenspital, Vienna, Austria.
J Clin Pharm Ther. 2006 Apr;31(2):149-52. doi: 10.1111/j.1365-2710.2006.00715.x.
The aim of the current study was to evaluate the short-term effects of anti-tumour necrosis factor alpha (infliximab) therapy on serum cartilage oligomeric matrix protein (COMP) levels, a possible biomarker of cartilage destruction.
Nine consecutive patients with active psoriatic arthritis (PsA) were treated with infliximab for 6 weeks. Serum COMP levels were measured and correlated to pre-established disease activity outcome variables: pain as assessed by the patient, using the 100 mm visual analogue scale (VAS), duration of morning stiffness (MGST), swollen joint count (SJC), tender joint count (TJC), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
Significant improvements in MGST, VAS, SJC and TJC values were observed after 6 weeks of therapy. Similar significant improvements were demonstrated in the ACR response rate and in eight (89%) patients the ACR20 was achieved. ESR and CRP decreased significantly over 6 weeks. Serum COMP levels also decreased significantly after 6 weeks of treatment (12.99 +/- 1.71 baseline, 10.22 +/- 1.1 after 6 weeks, P < 0.008).
The results of our study suggest that short-term therapy with infliximab leads to decreased COMP levels in patients with PsA. COMP seems to be a good candidate for a biomarker reflecting cartilage response to this treatment in PsA patients.
本研究旨在评估抗肿瘤坏死因子α（英夫利昔单抗）治疗对血清软骨寡聚基质蛋白（COMP）水平的短期影响，COMP可能是软骨破坏的生物标志物。
连续9例活动性银屑病关节炎（PsA）患者接受英夫利昔单抗治疗6周。测量血清COMP水平，并将其与预先确定的疾病活动结果变量相关联：患者评估的疼痛，采用100mm视觉模拟量表（VAS）、晨僵持续时间（MGST）、肿胀关节计数（SJC）、压痛关节计数（TJC）、红细胞沉降率（ESR）和C反应蛋白（CRP）。
治疗6周后，MGST、VAS、SJC和TJC值有显著改善。ACR反应率也有类似的显著改善，8例（89%）患者达到ACR20。ESR和CRP在6周内显著下降。治疗6周后血清COMP水平也显著下降（基线时为12.99±1.71，6周后为10.22±1.1，P<0.008）。
我们的研究结果表明，英夫利昔单抗短期治疗可使PsA患者的COMP水平降低。COMP似乎是反映PsA患者软骨对该治疗反应的生物标志物的良好候选者。
